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Ladies and Gentlemen,
During the past 150-200 years there have been many 
remarkable advances in medicine; the discovery of insulin, of 
penicillin, the virtual abolition of diseases such as smallpox, 
unlocking the secrets of DNA, to name but a few. But the 
greatest discovery of all, the one that has by far brought the 
most benefi t to mankind, has to be the discovery of 
anaesthesia. Without anaesthesia few, if any, of the advances 
in surgery we take so much for granted today would have been 
possible. On average about 200 000 surgical operations are 
performed annually in the Netherlands, and worldwide that 
number is more that 10 million. Few of these would be possible 
without anaesthesia. Just consider what patients undergoing 
surgery in the days before anaesthesia suffered, and compare 
that with how it is today. 
Until the advent of anaesthesia, a surgeon’s prowess was 
measured not by morbidity or mortality (both were 
exceptionally high by today’s standards) but typically by the 
time he took to operate. The most common operation, 
amputation of a limb, often could be performed in minutes. 
The French army surgeon, Larrey, recorded that during the 
Battle of Borodino, one of the bloodiest single-day battles of 
the Napoleonic Wars, he carried out 200 amputations on 
injured soldiers, all of course without anaesthesia.
During the fi rst half of the 19th century the Lancet published 
weekly lists of operations at London teaching hospitals, and 
many interesting operations were reported in detail. In the year 
from October 1826 to September 1827 a total of 213 operations 
were reported, including lithotomies, strangulated hernias, 
amputations, mastectomies and excision of the mandible. All 
were performed without anaesthesia. A typical case was that of 
a young girl described as being of small stature and feeble habit 
who had a stone in her bladder. The operation commenced at 2 
o’clock in the afternoon and fi nished at half past fi ve. The pain 
was reported to be “as severe as can be conceived and 
altogether without remission”. Can you even begin to imagine 
the suffering and agony endured by that poor girl and by many 
other wretched patients like her? 
In the days before anaesthesia many patients were taken to the 
limits of their endurance, and beyond, without much hope of 
subsequent cure. Indeed surgery was often considered as the last 
resort, often not carried out until the patient was in extremis. The 
discovery of anaesthesia was to change this in a dramatic way.
The discovery of general anaesthesia is a remarkable story rich 
with tales of impropriety, noble ambition and infl ated egos, a 
story that would not be out of place in a modern television soap 
drama. The fi rst practitioner of modern general anaesthesia was 
Crawford Long in the early 1840s. Unfortunately he did not 
report his work until 1849, by which time William Morton’s 
fame was already well established. In 1844, the Connecticut 
dentist Horace Wells started using nitrous oxide in his practice. 
However, when he went to demonstrate nitrous oxide 
anaesthesia to a larger audience at the Harvard Medical School 
in Boston, the affair was a fi asco. The patient complained of pain 
and Wells was hissed out of the room as a fraud. He gave up 
dentistry, became a chloro form addict, and travelled round the 
country with a troop of performing canaries. He committed 
suicide in 1848, aged 33 years. 
A colleague of Horace Wells, William Morton, is generally 
credited with the introduction of ether anaesthesia. On the 
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morning of Friday 16th October 1846, in front of an invited 
audience in the Bullfi nch operating theatre of the Massachusetts 
General Hospital in Boston, Morton administered ether to 
Edward Abbott for the excision of a tumour from his neck. This 
was the fi rst successful public demonstration of anaesthesia with 
ether in man. A newspaper reporter was present in the audience, 
and thus the discovery of surgical anaesthesia soon spread. Ether 
anaesthesia was being used in Europe within 2 months of 
Morton’s demonstration. 
There followed several years of unedifying wrangling between 
Morton, Jackson, who had suggested using ether to Morton, 
and Wells as to who deserved credit for the discovery of 
anaesthesia, with Wells eventually committing suicide, Jackson 
dying in an insane asylum and Morton dying penniless at the 
age of 48. This was a sad backdrop to one of the most 
momentous discoveries of modern pharmacology. Morton was 
never offi cially recognized in his lifetime as the pioneer of 
ether anaesthesia and died a disappointed man. Time, however, 
was to vindicate his claim. The inscription on his tombstone, 
composed by Henry Bigelow, Professor of Pharmacology in 
Boston, reads: “Inventor and Revealer of Inhalation 
Anaesthesia: Before Whom, in All Time, Surgery was Agony; 
By Whom, Pain in Surgery was Averted and Annulled; Since 
Whom, Science has Control of Pain”.
Within a few years of Morton’s historical demonstration ether 
anaesthesia had become commonplace. Chloroform was 
introduced soon after ether, by the Scottish obstetrician James 
Young Simpson in 1847, and for about one hundred years ether 
and chloroform had no rivals. Indeed it was not until the 
introduction of halothane in 1956 that the popularity of ether 
waned. The fi rst half of the twentieth century saw the 
introduction of a variety of volatile liquids and gases as 
anaesthetics. Most of these were explosive, toxic or both, and 
are now only of historical interest. Of the three pillars of early 
anaesthetic practice - nitrous oxide, chloroform and ether - 
only nitrous oxide remains in regular use, and even its 
popularity has waned considerably in recent years.
Today in anaesthesia we have some of the most potent and 
potentially dangerous drugs in medicine, drugs we use to take 
our patients on that journey from life towards death called 
anaesthesia, what the Edinburgh anaesthetist, John Gillies, very 
aptly described as “physiological trespass”. As anaesthetists we 
take away our patients ability to breathe for themselves, remove 
their protective refl exes and, perhaps the greatest trespass of 
all, we render them unconscious; we take from them, albeit 
temporarily, that what is ‘the person’. As an example of just 
how potent some of our drugs are, consider the opioid, 
sufentanil, widely used in anaesthesia as an analgesic. The little 
sachet of sugar we use with our coffee contains 5 g sugar. If 
instead of sugar the sachet contained sufentanil, I would need 
to dissolve its contents into 25 million litres water, the 
equivalent of 10 Olympic-size swimming pools, to achieve a 
concentration equivalent to that used clinically. Again if this 
sachet contained sufentanil there would be enough to render 
more than 20 000 people deeply unconscious and unable to 
breath. Without expert help from an anaesthesiologist they 
would all die within 3-4 minutes. 
How do anaesthetics work? 
The exceptionally wide range of compounds that possess 
anaesthetic activity has long intrigued anaesthesiologists and 
pharmacologists alike. Today, more than 160 years after the 
discovery of anaesthesia, research into the mechanisms of 
anaesthesia continues unabated. As an editor of the journal 
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Anesthesia and Analgesia, I deal with about 200 manuscripts 
submitted annually to my section, Anaesthetic Pharmacology. 
One quarter of these report research into some aspect of the 
mechanism of anaesthesia. 
Theories about how anaesthetics work have been as diverse as 
the compounds themselves. An early suggestion, made in 1847 
by von Bibra and Harless, was that anaesthetics dissolve and 
remove lipids in the brain.
1
 Happily, this idea proved to be false 
or the anaesthetic revolution might have been short-lived. 
Around the turn of the 20th century two investigators, Hans 
Meyer and Charles Overton, independently observed that the 
anaesthetic potency of a wide range of compounds was highly 
correlated with their solubility in olive oil, i.e. their lipid 
solubility.
2,3
 The Meyer-Overton relationship as it came to be 
known was taken to imply that anaesthesia was produced by 
perturbing the lipid structure of neuronal membranes. 
Lipid theories of anaesthesia fell broadly into four different 
camps. Anaesthetics were said either to increase lipid fl uidity, 
trigger lipid phase transitions, to change lipid bilayer 
dimensions or to alter membrane permeability. All of these 
had serious problems. For example, an increase in membrane 
disorder (increase fl uidity)  was proposed as a basis for 
anaesthesia. However, the changes produced by anaesthetics 
are extremely small and can be mimicked by a very small rise 
in temperature. Further, these theories cannot account for the 
fact that anaesthetic enantiomers usually have markedly 
different anaesthetic potencies, yet are equally effective in 
disrupting lipid bilayers. Finally the discovery of inhaled 
compounds with potencies that do not correlate with 
lipophilicity added a further nail in the coffi n of lipid theories.
4
 
The seminal paper by Nick Franks and Bill Lieb from the 
Imperial College, London, in 1984, showing that a wide variety 
of anaesthetics could inhibit lipid-free preparations of the 
fi refl y luciferase enzyme by direct binding shifted the focus 
from lipids as targets of anaesthetic activity.
5
 There is now a 
consensus that anaesthetics act by binding to protein, 
specifi cally ligand-gated ion channels such as the -
aminobutyric acid type A (GABAA), the glycine receptor and 
the N-methyl-D-aspartate (NMDA) receptor.
6
 Intravenous 
anaesthetics, with the exception of ketamine, and the volatile 
anaesthetics cause unconsciousness primarily via GABAA 
receptors in the brain containing beta3 subunits, whereas 
receptors containing beta2 subunit, which make up more than 
50% of all GABAA receptors in the central nervous system, 
mediate sedation. Some of the most convincing evidence for 
the role of the GABAA receptor has come from molecular 
genetics. Mutation of a single critical amino acid within the 
receptor renders an animal resistant to the hypnotic and 
immobilizing effects of anaesthetics.
7
 The anaesthetic gases 
nitrous oxide, xenon, and cyclopropane and the intravenous 
anaesthetic ketamine show little, if any, activity at GABAA or 
glycine receptors, but strongly inhibit the NMDA receptors 
and open TREK-1 potassium channels. 
In addition to their central actions in producing 
unconsciousness, volatile anaesthetics produce immobility 
primarily by actions on the spinal cord,
8
 but there does not 
seem to be a dominant molecular mechanism that accounts for 
their spinal actions. A recent study showed that GABAA and 
glycine receptors only contribute 30-40% to their depressant 
actions on spinal neurones.
9
 Two-pore-domain potassium 
channels, which act as regulators of membrane excitability, 
have emerged recently as a target for the immobilizing actions 
of the volatile anaesthetics.
10
 The two-pore channel TREK-1 is 
particularly sensitive to inhalational anaesthetics, and TREK-1-
defi cient mice are resistance to anaesthesia. 
Anaesthesia - A medical and pharmacological revolution
7
The theories of anaesthesia that concentrate on actions on ion 
channels and receptors do not provide a fully satisfactory 
explanation as to how the state of anaesthesia is actually 
generated. The potentiation of GABA receptors, for example, 
may be more accurately regarded as an action rather than a 
 mechanism. The one defi ning feature anaesthetics have in 
common is that they induce a reversible loss of consciousness. 
Anaesthesia can therefore be considered as a state in which, as 
a result of reversible, drug-induced unconsciousness, the 
patient neither perceives nor recalls noxious stimuli.
11
However, the question ‘How does anaesthesia occur?’ is 
unanswerable in the absence of a defi nition of consciousness.
12
 
The “dynamic core” of consciousness is thought to be 
coordinated synchronous activity mediated by electrical 
synapses known as gap junctions under the control of the 
thalamus.
13,14
 A useful analogy is of a symphony orchestra. 
Individual musicians or groups of musicians each process 
musical information in a particular way. The fi nal product is 
coherent music rather than meaningless noise because of the 
organization that is achieved by the conductor. Distinct 
neuronal subpopulations of the cortex (the individual 
musicians) are synchronized by resonance with a common 
rhythmical oscillator (the conductor), such as 40-Hz 
pacemaker neurons in the thalamus. Anaesthetics, by their 
actions on ion channels, hyperpolarize neurons in these 
thalamocortical loops, uncoupling and disrupting this 
coherent cortical oscillation. Thus anaesthesia may dependent 
less on depressive actions of anaesthetics but instead result 
from the disorganization or disintegration of cognitive 
processes that bind information together.
15
 
Long-term effects of anaesthesia
As anaesthesiologists we are used to thinking on a short time 
scale. The drugs we use are among the fastest acting in clinical 
medicine, with onset and offset times measured in seconds or 
minutes. We often assume, therefore, that their effects dissipate 
quickly without long-term sequelae. However, in addition to 
their profound immediate effects, anaesthetics can have subtle 
but measurable long-term consequences, some benefi cial, 
others potentially damaging. The discovery that volatile 
anaesthetics and some opioids protect the myocardium from 
ischaemia, a process known as anaesthetic preconditioning, is 
an obvious benefi cial effect that can manifest for several days 
after the anaesthetic has been withdrawn. On the other hand 
volatile anaesthetics can cause profound and long-lasting 
changes in gene and protein expression in the brain that could 
adversely infl uence cerebral function far beyond the time of 
anaesthesia.
16,17
 These changes may contribute to long-term 
effects such as memory alteration and cognitive dysfunction 
reported mainly by elderly patients after anaesthesia and 
surgery. Inhalational anaesthetics may enhance 
microaggregation of the amyloid  peptide, resulting in long-
lasting increases of the neurotoxic form of amyloid in the brain 
of susceptible subjects.
18
 However, it must be emphasised that 
the most extensive clinical trials published to date have neither 
proven nor excluded a direct causal link between anaesthetics 
and cognitive impairment.
What may the future hold for anaesthetic 
pharmacology?
Can we expect many new and revolutionary drugs reaching 
clinical application in the future? I think the answer must be, 
unlikely. One reason is that, while the drugs available today 
may not be ideal, they are close enough to make it diffi cult to 
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improve upon them without very considerable effort and 
expense. Drug development is largely determined by 
commercial considerations. The likely return on 
pharmaceutical company investment in new anaesthetics is low 
compared with other areas of medicine, and the costs of failure 
extremely high. In recent years attempts to develop new water-
soluble intravenous agents as alternatives to propofol have not 
been successful because of unwanted effects or slow recovery. 
The success of remifentanil and its esterase metabolism has 
encouraged attempts at developing compounds with recovery 
profi les faster than propofol.
19,20
 The question is, however, do 
we need or want such ultra-rapid recovery from anaesthesia – 
is it possible for an anaesthetic to wear off too quickly? At the 
other end of the spectrum is propofol phosphate, a water-
soluble propofol prodrug which is enzymatically converted to 
propofol. Because it is a prodrug the onset is much slower than 
for propofol. Again, it is diffi cult to see the advantage of 
modifying a drug in such a way as to slow its onset of action 
when almost the entire focus of anaesthetic drug development 
has been to achieve the opposite effect.
21
 
There is one drug currently undergoing phase III clinical trials, 
sugammadex, that does have the potential to revolutionise one 
aspect of anaesthesia, the management of neuromuscular 
block. Sugammadex is a modifi ed -cyclodextrin that was 
engineered to specifi cally reverse the effects of aminosteroid 
muscle relaxants, specifi cally rocuronium. It rapidly removes 
rocuronium molecules from the plasma by encapsulating them 
within its inner structure, forming a water-soluble complex 
that is renally excreted.
22
 Sugammadex is ineffective against 
succinylcholine and benzylisoquinolinium neuromuscular 
blockers because it cannot form inclusion complexes with 
these drugs. Sugammadex will  facilitate the use of rocuronium 
for rapid sequence induction of anaesthesia by providing a 
faster onset-offset profi le than that seen with succinylcholine. 
Why ever give succinylcholine if you can give high doses of 
rocuronium and then reverse it more quickly than the 
succinylcholine would wear off?  
Genetics
Molecular biology and transgenic/knockout mouse biology has 
led in the last decades to very signifi cant advances in 
anaesthetic pharmacology. Studies in mice, for example, 
suggest that there are likely to be genetic factors that infl uence 
anaesthetic requirements.
23
 Understanding these genetic factors 
could help provide still safer anaesthesia. In the coming decade 
genomics, the study of genetic variants has the potential to 
answer some fundamental questions in anaesthetic 
pharmacology and in clinical anaesthesia. Increasingly 
genomic technology is providing valuable information about 
DNA variants responsible for the variability in patients’ 
responses to drugs, in particular variability due to single-
nucleotide polymorphism (SNP). The exploitation of 
genomics, by offering the opportunity to customize individual 
patients’ drug therapy to their genotype, may prove tobe the 
next revolution in anaesthesia. The increasing speed of PCR 
analysis of genetic material - what 5 years ago took weeks now 
takes only hours - will make rapid preoperative screening of 
patients for genetic variation a reality. Whether this will be 
economically viable or clinically acceptable remains to be seen.
Ladies and Gentlemen,
The pharmacological basis of anaesthesia has changed 
dramatically during the 40 years I have worked in the 
speciality. When I started my training in 1967, pancuronium 
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had not yet been discovered, and tubocurarine and gallamine 
were the standard muscle relaxants. I was taught not only how 
to administer the relatively new anaesthetic, halothane, but 
also how to use ether and cyclopropane. Today we have much 
more sophisticated pharmacological tools at our disposable, 
many of which I have already mentioned in this lecture, and 
we have a much better understanding about their 
pharmacology than was ever dreamed about by our 
predecessors. 
Anaesthesiologists have made very signifi cant contributions 
not only to the pharmacology of drugs related specifi cally to 
anaesthesia, but also to the wider fi eld of general 
pharmacology. One fi eld where they have been especially 
productive is in PK/PD modelling. Indeed one of the early 
pioneers in this fi eld was Chris Hull, professor of anaesthetics 
in Newcastle upon Tyne, and his initial ideas were subsequently 
expanded upon by Don Stanski and Lewis Sheiner from the 
departments of anaesthesiology and pharmacology at the 
University of Stanford in California. And our own department 
in Leiden has been among the world leaders in research and 
development in this and related fi elds of anaesthetic 
pharmacology during the past three decades. Despite all the 
remarkable advances of the past decades, there remain many 
unanswered questions, suffi cient to keep those interested in 
this branch of pharmacology busy for many years to come. I 
am confi dent that, as in the past, the department of 
anaesthesiology of the LUMC will continue in the future to 
maintain its reputation as world leaders in research into 
anaesthetic pharmacology.
Ik heb gezegd.
10
Prof.dr. J.G. Bovill
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The discovery of anaesthesia ranks as one of most far-reaching 
medical discoveries of the past 150-200 years. Without 
anaesthesia few, if any, of the advances in surgery 
we take so much for granted today would have been possible. 
The pharmacological basis of anaesthesia has changed 
dramatically during the 40 years I have worked in the speciality. 
Today we have some of the most potent and potentially 
dangerous drugs in medicine, drugs we use to take our patients 
on that journey from life towards death called anaesthesia. 
Anaesthesiologists have made very signifi cant contributions 
not only to the pharmacology of drugs related specifi cally to 
anaesthesia, but also to the wider fi eld of general pharmacology. 
Our department in Leiden has been among the world leaders in 
research and development in anaesthetic pharmacology during 
the past three decades. I am confi dent that it will continue to 
maintain this reputation well into the future.
